[go: up one dir, main page]

EA201891008A2 - Лечение симптомов, связанных с андроген-депривационной терапией - Google Patents

Лечение симптомов, связанных с андроген-депривационной терапией

Info

Publication number
EA201891008A2
EA201891008A2 EA201891008A EA201891008A EA201891008A2 EA 201891008 A2 EA201891008 A2 EA 201891008A2 EA 201891008 A EA201891008 A EA 201891008A EA 201891008 A EA201891008 A EA 201891008A EA 201891008 A2 EA201891008 A2 EA 201891008A2
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
symptoms associated
androgen
deprivation therapy
therapy
Prior art date
Application number
EA201891008A
Other languages
English (en)
Other versions
EA034553B1 (ru
EA201891008A3 (ru
Inventor
Чарльз Томас Бенсон
Ханна Ю
Рейчел Ричей
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201891008A2 publication Critical patent/EA201891008A2/ru
Publication of EA201891008A3 publication Critical patent/EA201891008A3/ru
Publication of EA034553B1 publication Critical patent/EA034553B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)

Abstract

Описан способ лечения симптомов, связанных с андроген-депривационной терапией, включающий введение пациенту, нуждающемуся в таком лечении, эффективного количества соединения формулы Iили его фармацевтически приемлемой соли.
EA201891008A 2014-09-11 2015-09-08 Способ получения соединения для лечения симптомов, связанных с антиандрогенной терапией EA034553B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049192P 2014-09-11 2014-09-11

Publications (3)

Publication Number Publication Date
EA201891008A2 true EA201891008A2 (ru) 2018-09-28
EA201891008A3 EA201891008A3 (ru) 2019-03-29
EA034553B1 EA034553B1 (ru) 2020-02-19

Family

ID=54151401

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201790220A EA033606B1 (ru) 2014-09-11 2015-09-08 Лечение симптомов, связанных с андроген-депривационной терапией
EA201891008A EA034553B1 (ru) 2014-09-11 2015-09-08 Способ получения соединения для лечения симптомов, связанных с антиандрогенной терапией

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201790220A EA033606B1 (ru) 2014-09-11 2015-09-08 Лечение симптомов, связанных с андроген-депривационной терапией

Country Status (23)

Country Link
US (4) US10758515B2 (ru)
EP (2) EP3375444A1 (ru)
JP (4) JP6893171B2 (ru)
KR (5) KR20190015628A (ru)
CN (4) CN108440497A (ru)
AP (1) AP2017009795A0 (ru)
AU (2) AU2015315431C1 (ru)
BR (2) BR112017002449B1 (ru)
CA (2) CA3067289C (ru)
EA (2) EA033606B1 (ru)
ES (1) ES2779978T3 (ru)
HK (1) HK1252811A1 (ru)
IL (3) IL279209B2 (ru)
JO (2) JOP20180072A1 (ru)
MA (1) MA45416A (ru)
MX (3) MX373322B (ru)
MY (2) MY195767A (ru)
NZ (1) NZ728612A (ru)
SG (2) SG10201809673RA (ru)
TW (1) TWI616201B (ru)
UA (1) UA120099C2 (ru)
WO (1) WO2016040234A1 (ru)
ZA (1) ZA201802680B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
AU2021213297A1 (en) 2020-01-27 2022-08-18 Eirgen Pharma Ltd. Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007536A (es) * 2003-01-13 2005-10-20 Gtx Inc Sintesis a gran escala de moduladores de receptor de androgeno selectivos.
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
EP2024332A1 (en) 2006-05-31 2009-02-18 Glaxo Group Limited Novel heterocyclic compounds
US20090156614A1 (en) * 2006-07-19 2009-06-18 Dalton James T Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
US7443672B2 (en) 2006-10-03 2008-10-28 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Video graphics array (VGA) card assembly
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
ES2413504T3 (es) 2007-12-21 2013-07-16 Ligand Pharmaceuticals Inc. Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos
BRPI0912394A2 (pt) * 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol
WO2009155481A1 (en) * 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) * 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) * 2010-12-27 2012-08-09 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換−環状アミノ誘導体からなる医薬
AU2013339167B2 (en) * 2012-10-31 2018-03-15 Fujifilm Corporation Novel amine derivative or salt thereof
CN105814052B (zh) * 2013-12-09 2018-01-12 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Also Published As

Publication number Publication date
AU2015315431B2 (en) 2018-03-08
JP2017527584A (ja) 2017-09-21
MY198753A (en) 2023-09-23
JP6893171B2 (ja) 2021-06-23
US20200390744A1 (en) 2020-12-17
BR112017002449B1 (pt) 2022-08-09
IL279209A (en) 2021-01-31
WO2016040234A1 (en) 2016-03-17
ZA201802680B (en) 2020-08-26
BR112017002449A2 (pt) 2017-12-05
IL258651B (en) 2021-02-28
CN113521068A (zh) 2021-10-22
CA2956514A1 (en) 2016-03-17
IL279209B2 (en) 2023-02-01
AU2018202714A1 (en) 2018-05-17
JP2019089795A (ja) 2019-06-13
EP3375444A1 (en) 2018-09-19
ES2779978T3 (es) 2020-08-21
CA3067289A1 (en) 2016-03-17
EA034553B1 (ru) 2020-02-19
KR20210083370A (ko) 2021-07-06
JO3609B1 (ar) 2020-08-27
EA201790220A1 (ru) 2017-07-31
MX2021014120A (es) 2022-01-04
US20240148694A1 (en) 2024-05-09
KR102619415B1 (ko) 2024-01-02
MA45416A (fr) 2019-04-24
EP3191094B1 (en) 2020-02-19
CN108440497A (zh) 2018-08-24
AP2017009795A0 (en) 2017-03-31
MX373322B (es) 2020-05-21
MX2017003140A (es) 2017-05-23
JP2023145479A (ja) 2023-10-11
NZ728612A (en) 2018-03-23
CN106794178A (zh) 2017-05-31
CN113651797A (zh) 2021-11-16
EA033606B1 (ru) 2019-11-08
IL250291A0 (en) 2017-03-30
IL258651A (en) 2018-06-28
US20190111039A1 (en) 2019-04-18
EA201891008A3 (ru) 2019-03-29
MX391447B (es) 2025-03-21
CA3067289C (en) 2023-04-04
AU2018202714B2 (en) 2019-06-20
KR102024493B1 (ko) 2019-09-23
KR20190015628A (ko) 2019-02-13
US10799478B2 (en) 2020-10-13
SG11201701630VA (en) 2017-03-30
UA120099C2 (uk) 2019-10-10
SG10201809673RA (en) 2018-12-28
KR20220132669A (ko) 2022-09-30
MY195767A (en) 2023-02-10
US20170172992A1 (en) 2017-06-22
JOP20180072A1 (ar) 2019-01-30
KR20170040338A (ko) 2017-04-12
BR122018007412B1 (pt) 2022-08-23
AU2015315431A1 (en) 2017-03-09
KR20180041268A (ko) 2018-04-23
HK1252811A1 (en) 2019-06-06
TW201618782A (zh) 2016-06-01
US10758515B2 (en) 2020-09-01
IL279209B (en) 2022-10-01
JP2022000432A (ja) 2022-01-04
JP7349480B2 (ja) 2023-09-22
TWI616201B (zh) 2018-03-01
EP3191094A1 (en) 2017-07-19
AU2015315431C1 (en) 2018-08-02
JP6938550B2 (ja) 2021-09-22
CA2956514C (en) 2023-04-18
IL250291B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
PH12017500493A1 (en) Combination therapy
PH12015501920B1 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
TW201613578A (en) Pharmaceutical combinations
MX388722B (es) Compuestos para tratar el cancer de ovario.
EA201491500A1 (ru) Способы лечения фиброза
MX357763B (es) Tratamiento para cancer pancreatico.
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
EA202193276A1 (ru) Способы лечения холангиокарциномы
EA201891008A2 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
MX374354B (es) Método de curación de heridas.
AR099416A1 (es) Terapia combinada para la hipertensión resistente
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
EA201690214A1 (ru) Способ лечения гипертрофической кардиомиопатии
EA202090336A1 (ru) Соединения, их соли и способы лечения заболеваний
UA104030U (ru) Способ лечения больных с обострением хронического бронхита вирусной этиологии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): RU